Market cap
$28 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$22 Mln
-
ROE
-1.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.1
-
Face value
--
-
Shares outstanding
3,249,530
10 Years Aggregate
CFO
CA$-698.12 Mln
EBITDA
CA$-746.96 Mln
Net Profit
CA$-897.76 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Liminal BioSciences - ADR
| 161.5 | 0.9 | 36.4 | 88.9 | -57.5 | -70.2 | -48.8 |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Liminal BioSciences - ADR
| -70.2 | -74.0 | -49.9 | -95.6 | -81.1 | -37.8 | -31.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Liminal BioSciences - ADR
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is... developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada. Read more
-
Chief Exec. Officer
Mr. Bruce Pritchard BA, CA, FIOD
-
Chief Exec. Officer
Mr. Bruce Pritchard BA, CA, FIOD
-
Headquarters
Laval, QC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Liminal BioSciences - ADR
What is the current share price of Liminal BioSciences Inc - ADR Today?
The share price of Liminal BioSciences Inc - ADR is $8.50 (NASDAQ) as of 26-Sep-2023 09:30 EDT. Liminal BioSciences Inc - ADR has given a return of -57.47% in the last 3 years.
What is the current PB & PE ratio of Liminal BioSciences Inc - ADR?
Since, TTM earnings of Liminal BioSciences Inc - ADR is negative, P/E ratio is not available.
The P/B ratio of Liminal BioSciences Inc - ADR is 0.44 times as on 26-Sep-2023, a 91 discount to its peers’ median range of 4.83 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.03 |
0.03 |
2021 |
-0.07 |
0.08 |
2020 |
-0.09 |
0.50 |
2019 |
-0.08 |
0.19 |
2018 |
0.00 |
0.00 |
What is the 52 Week High and Low of Liminal BioSciences Inc - ADR?
The 52-week high and low of Liminal BioSciences Inc - ADR are Rs -- and Rs -- as of 02-Sep-2026.
What is the market cap of Liminal BioSciences Inc - ADR?
Liminal BioSciences Inc - ADR has a market capitalisation of $ 28 Mln as on 26-Sep-2023. As per SEBI classification, it is a company.
Should I invest in Liminal BioSciences Inc - ADR?
Before investing in Liminal BioSciences Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.